Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Biogen (BIIB)
NASDAQ:BIIB
Holding BIIB?
Track your performance easily
BIIB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$189.44 - $270.50
Previous Close$204.76
Volume879.06K
Average Volume (3M)995.57K
Market Cap
$29.83B
Enterprise Value$36.49B
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$6.66B
Price to Earnings (P/E)25.8
Beta0.46
Next Earnings
Oct 22, 2024EPS Estimate
$3.77Last Dividend Ex-Date
Feb 02, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)7.94
Shares Outstanding145,661,642
10 Day Avg. Volume683,879
30 Day Avg. Volume995,567
Standard Deviation0.10
R-Squared0.00041
Alpha0.00294
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)3.08
Price to Cash Flow (P/CF)N/A
P/FCF Ratio11.70
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.77
Enterprise Value/Gross Profit5.00
Enterprise Value/Ebitda13.72
Forecast
1Y Price Target
$275.89Price Target Upside34.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
Biogen News
PremiumCompany Announcements
Biogen Enhances Financial Flexibility with New Credit Facility
Bulls Say, Bears Say
Bulls Say
Financial PerformanceSkyclarys 2Q24 WW sales of $100M exceeded consensus estimates, largely driven by an impressive ex-US figure.
Market OpportunityA total addressable market of more than $6 billion could make this a significant opportunity for Biogen.
Sales PerformanceLeqembi's launch continues to accelerate with sales up 111% Q/Q.
Bears Say
Clinical TrialsDapirolizumab pegol's Ph 2b study did not meet the primary endpoint of BICLA.
Regulatory SetbacksThe European Medicines Agency's Committee for Medicinal Products for Human Use returned a negative opinion on lecanemab as treatment for early Alzheimer's disease.
Sales PerformanceSkyclarys US sales of $76M is below cons $82M.
---
Ownership Overview
1.99% Insiders
38.44% Mutual Funds
54.61% Other Institutional Investors
4.96% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BIIB FAQ
What was Biogen’s price range in the past 12 months?
Biogen lowest stock price was $189.44 and its highest was $270.50 in the past 12 months.
What is Biogen’s market cap?
Currently, no data Available
When is Biogen’s upcoming earnings report date?
Biogen’s upcoming earnings report date is Oct 22, 2024 which is in 52 days.
How were Biogen’s earnings last quarter?
Biogen released its earnings results on Aug 01, 2024. The company reported $5.28 earnings per share for the quarter, beating the consensus estimate of $4.068 by $1.212.
Is Biogen overvalued?
According to Wall Street analysts Biogen’s price is currently Undervalued.
Does Biogen pay dividends?
Biogen pays a Notavailable dividend of $22.23 which represents an annual dividend yield of N/A. See more information on Biogen dividends here
What is Biogen’s EPS estimate?
Biogen’s EPS estimate is $3.77.
How many shares outstanding does Biogen have?
Biogen has 145,661,640 shares outstanding.
What happened to Biogen’s price movement after its last earnings report?
Biogen reported an EPS of $5.28 in its last earnings report, beating expectations of $4.068. Following the earnings report the stock price went down -1.173%.
Which hedge fund is a major shareholder of Biogen?
Among the largest hedge funds holding Biogen’s share is PRIMECAP Management Co. It holds Biogen’s shares valued at 4B.
---
Biogen Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$275.89 (34.74% Upside)
$275.89 (34.74% Upside)
Blogger Sentiment
Bullish
BIIB Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 419.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.36%
12-Months-Change
Fundamentals
Return on Equity
7.63%
Trailing 12-Months
Asset Growth
6.55%
Trailing 12-Months
Company Description
Biogen
Incorporated in 1978, Massachusetts-based Biogen, Inc. is a biopharmaceutical company, which discovers, develops, and delivers therapies for the treatment of neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis.
---
BIIB Company Deck
---
BIIB Earnings Call
Q2 2024
0:00 / 0:00
---
BIIB Revenue Breakdown
73.68% Product revenue
17.18% Revenue from anti-CD20 therapeutic programs
9.14% Other
---
BIIB Stock 12 Month Forecast
Average Price Target
$275.89
▲(34.74% Upside)
Technical Analysis
Best Analysts Covering BIIB
1 Year
1 Year Success Rate
12/37 ratings generated profit
1 Year Average Return
-2.43%
reiterated a buy rating last month
Copying Marc Goodman's trades and holding each position for 1 Year would result in 32.43% of your transactions generating a profit, with an average return of -2.43% per trade.
---